App-Quantinova.ai

NIVES study: A phase II trial of nivolumab (NIVO) plus stereotactic body radiotherapy (SBRT) in II and III line of patients (pts) with metastatic renal cell carcinoma (mRCC).

Cristina Masini - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Nivolumab

A phase 3, open-label, randomized study of nivolumab plus ipilimumab or standard of care (SoC) vs SoC alone in patients (pts) with previously untreated unresectable or metastatic urothelial carcinoma (mUC; CheckMate 901).

Matt D. Galsky - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

Phase 1/2 study of safety/efficacy using trabectedin, ipilimumab and nivolumab triple therapy as first line treatment of advanced soft tissue sarcoma.

Erlinda Maria Gordon - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

Efficacy and safety of nivolumab (Nivo) in patients (pts) with advanced or recurrent uterine cervical or corpus cancers.

Kosei Hasegawa - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

Nivolumab

Factors predicting the use of immunotherapy for patients with advanced melanoma.

Richard Wayne Joseph - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

Characterization of complete responders to combination nivolumab (nivo) and ipilimumab (ipi) in patients (pts) with advanced, unresectable melanoma.

Allison Betof Warner - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

Safety and preliminary activity data from a single center phase II study of triplet combination of nivolumab (N) with dabrafenib (D) and trametinib (T) [trident] in patients (Pts) with BRAF-mutated metastatic melanoma (MM).

Hussein Abdul-Hassan Tawbi - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

Immune gene profiling of pretreatment tumor samples in "real-world" advanced melanoma patients treated with anti-PD-1 and/or anti-CTLA-4.

Elisa A. Rozeman - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

Phase 1 study to evaluate safety and efficacy of nivolumab (nivo) + ipilimumab (ipi) + external beam radiotherapy (RT) in patients with metastatic melanoma.

Michael A. Postow - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

BMS-986205, an indoleamine 2,3-dioxygenase 1 inhibitor (IDO1i), in combination with nivolumab (NIVO): Updated safety across all tumor cohorts and efficacy in pts with advanced bladder cancer (advBC).

Josep Tabernero - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

Pegilodecakin with nivolumab (nivo) or pembrolizumab (pembro) in patients (pts) with metastatic renal cell carcinoma (RCC).

Nizar M. Tannir - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

ECHO-310: A phase 3, randomized trial of epacadostat + nivolumab + chemo vs EXTREME as first-line treatment of recurrent/metastatic SCCHN.

Ezra E.W. Cohen - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

Nivolumab (nivo) for patients (pts) with metastatic non-clear cell renal cell carcinoma (nccRCC): A single-institution experience.

Jad Chahoud - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

Preclinical development of sunitinib and nivolumab in osteosarcoma and synovial sarcoma: In vitro functional studies.

Emanuela Palmerini - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

In silico approach to inhibit the checkpoint protein PD-1by the monoclonal antibody nivolumab.

E.L. Albuquerque - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

Nivolumab

Clinical parameters predicting response and outcomes to immunotherapy in metastatic cancers.

Rohan Garje - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

Cost-effectiveness of nivolumab vs. ipilimumab/nivolumab vs. trifluridine/tipiracil or mFOLFOX6/cetuximab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer.

Jacqueline N. Chu - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

Efficacy and safety profile of PD-1 and pdl-1 inhibitors in African American patients.

Shahla Bari - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

Impact of comorbidity on immune checkpoint blockade tolerance across tumor types.

Sean Clark-Garvey - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Nivolumab

A review of the patterns of prescribing, efficacy and toxicities for patients receiving checkpoint inhibitors.

Peter Nightingale - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

Nivolumab

Filters

2342 Abstracts